Source: http://compliance-sec.com/secfilings/company/ewellness-healthcare/xbrl/2015/05-12-2015/index.html
Timestamp: 2017-11-20 15:17:23
Document Index: 309827386

Matched Legal Cases: ['arty 7', 'arty 43', 'arty 25', 'arty 30', 'arty 1', 'arty 43', 'arty 8']

Entity Registrant Name eWELLNESS HEALTHCARE Corp
Entity Central Index Key 0001550020
Entity Common Stock, Shares Outstanding 16,881,000
Name: DGT_DocumentAndEntityInformationAbstract
Namespace Prefix: DGT_
Cash $ 25,753 $ 900
Advances - related party 7,054
Prepaid Expenses 71,845 26,274
Total current assets 97,598 34,228
Property & equipment, net 7,226 3,231
Intangible assets, net 22,077 22,816
TOTAL ASSETS 126,901 60,275
Accounts payable and accrued expenses 139,162 174,044
Accounts payable -related party 43,056 56,155
Accrued expenses - related party 25,076 30,181
Accrued compensation 414,000 329,000
Short term note and liabilities 166,100
Total current liabilities 877,394 679,380
Convertible debt, net of discount 187,159 178,433
Total Liabilities 1,064,553 857,813
Preferred stock, authorized, 10,000,000 shares, $.001 value, 0 shares issued and outstanding
Common stock, authorized 100,000,000 shares, $.001 par value, 16,881,000 and 16,421,000 issued and outstanding, respectively 16,881 16,421
Additional Paid in Capital 1,263,625 1,087,320
Accumulated deficit (2,218,158) (1,901,279)
Total Stockholder's Equity (Deficit) (937,652) (797,538)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 126,901 $ 60,275
Accrued Liabilities Related Parties Current.
Name: DGT_AccruedLiabilitiesRelatedPartiesCurrent
Name: us-gaap_ProductLiabilityContingencyAccrualPresentValue
Common stock, shares issued 16,881,000 16,421,000
Common stock, shares outstanding 16,881,000 16,421,000
Executive compensation $ 186,000 $ 186,000
General and administrative 34,588 25,031
Professional fees 90,394 29,671
Research and development - related party 30
Total Operating Expenses 310,982 240,732
Loss from Operations (310,982) (240,732)
Gain on extinguishment of debt 11,323
Interest expense, related parties (1,078) (856)
Interest expense (16,142)
Loss before Income Taxes (316,879) (240,732)
Income tax expense (50)
Net Loss $ (316,879) $ (240,732)
Basic and diluted (loss) per share $ (0.02) $ (0.03)
Basic and diluted weighted average shares outstanding 16,740,778 9,200,000
Depreciation and amortization 950 449
Contributed services 97,500 1,500
Shares issued for services 9,389
Warrants issued for services 7,153
Convertible debt discount 8,726
Imputed interest - related party 1,078 856
Advances - related parties 7,054 (2,390)
Prepaid expense 16,074
Accounts payable and accrued expenses (34,880) 22,661
Accounts payable - related party (13,100)
Accrued expenses - related party (5,105) 18,506
Accrued compensation 85,000 186,000
Net cash used in operating activities (137,040) (14,006)
Cash flows from investing activities Purchase of equipment (4,207)
Net cash used in investing activities (4,207)
Common stock subscribed 146,100
Convertible loan payable 20,000 30,000
Net cash provided by financing activities 166,100 30,000
Net increase (decrease) in cash 24,853 15,994
Cash, beginning of period 900
Cash, end of period 25,753 15,994
Name: DGT_CashPaidAbstract
Name: DGT_ContributedServices
Increase Decrease in Accrued Liabilities Related Parties.
Name: DGT_IncreaseDecreaseInAccruedLiabilitiesRelatedParties
Proceeds From Common Stock Subscribed.
Name: DGT_ProceedsFromCommonStockSubscribed
eWellness Healthcare Corporation (f/k/a Dignyte, Inc.), (the “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011, to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. The Company has generated no revenues to date. Prior to the Share Exchange Agreement discussed below, other than issuing shares to its original shareholder, the Company never commenced any operational activities.
eWellness was incorporated in Nevada in May 2013. Following a share exchange detailed below we completed in April 2014, pursuant to which eWellness Corporation, a Nevada corporation became our wholly owned subsidiary, we abandoned our prior business plan and we are now pursuing eWellness Corporation’s historical businesses and proposed businesses. Our historical business and operations will continue independently. eWellness is an early-stage Los Angeles based corporation that seeks to provide a unique telemedicine platform that offers Distance Monitored Physical Therapy (DMpt) Programs utilizing its proprietary WWW.PHZIO.COM telemedicine platform initially to pre-diabetic, cardiac and health challenged patients, through contracted physician practices and healthcare systems, in addition to in-office sessions. Based on today’s insurance landscape, our main revenue source shall come from a combination of in-office and telemedicine visits. Amid ongoing challenges and changes within the healthcare industry, telemedicine is emerging as an increasingly attractive tool for delivering quality medical services.
On April 11, 2014, Digntye, Inc. (“Dignyte”), a publicly held Nevada corporation and eWellness Corporation (“Private Co”), a privately held company incorporated in Nevada, executed a Share Exchange Agreement (or “Initial Exchange Agreement”). Prior to the execution and delivery of the final Amended and Restated Share Exchange Agreement (the “Agreement”), the Board of Directors of Dignyte approved the Agreement and the transactions contemplated thereby. Similarly, the Board of Directors of the Private Co. approved the exchange. On April 25, 2014, immediately prior to the execution and delivery of the Agreement, Dignyte amended its certificate of incorporation to change its corporate name from “Dignyte, Inc.” to “eWellness Healthcare Corporation.”
Pursuant to the Agreement, eWellness Healthcare Corporation issued 9,200,000 shares of unregistered common stock, $.001 par value (the “common stock”) to the shareholders of the Private Co. in exchange for all outstanding shares of the Private Co.’s common stock. In addition, our former chief executive officer agreed: (i) to tender 5,000,000 shares of common stock back to the Company for cancellation; (ii) assign from his holdings, an additional 2,500,000 shares to the shareholders of the Private Co. resulting in a total of 11,700,000 shares owned by those shareholders; and, (iii) to a further assignment of an additional 2,100,000 shares to other parties as stated therein (collectively, the “CEO Stock Actions”).
As the parties satisfied all of the closing conditions, on April 30, 2014, we closed the Share Exchange. As a result, the Private Co. shareholders own approximately 76.97% of our issued and outstanding common stock, after giving effect to CEO Stock Actions.
Following the Share Exchange, we abandoned our prior business plan and we are now pursuing the Private Co.’s historical businesses and proposed businesses. The Private Co. is the surviving company under the share exchange and became a wholly owned subsidiary of the Company.
For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination. Consequently, the transaction is accounted for as a reverse-merger and recapitalization. eWellness Corporation is the acquirer for financial reporting purposes and Dignyte, Inc. is the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the transactions are those of eWellness Corporation and are recorded at the historical cost basis of eWellness Corporation, and the consolidated financial statements after completion of the transaction include the assets, liabilities and operations of eWellness Healthcare Corporation, and eWellness Corporation from the closing date of the transaction. Additionally all historical equity accounts and awards of eWellness Corporation, including par value per share, share and per share numbers, have been adjusted to reflect the number of shares received in the transaction.
The foregoing description of the Share Exchange Agreement does not purport to be complete and is qualified in its entirety by the Share Exchange Agreement, a copy of which is attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on May 10, 2014. At the execution of the Share Exchange Agreement, the total number of shares of common stock outstanding was 15,200,000.
The Company is in the initial phase of developing a unique telemedicine platform that offers Distance Monitored Physical Therapy Programs (“DMpt”) to pre-diabetic, cardiac and health challenged patients, through contracted physician practices and healthcare systems specifically designed to help prevent patients that are pre-diabetic from becoming diabetic. The Company’s activities are subject to significant risks and uncertainties, including failure to secure funding to operationalize the Company’s business plan.
The interim financial information of the Company as of periods ended March 31, 2015 and March 31, 2014 is unaudited. The balance sheet as of December 31, 2014 is derived from audited financial statements of eWellness Healthcare Corporation. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform to the accounting policies disclosed in ASU 2014-10. In the opinion of management, all adjustments which are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results that can be expected for the entire year ending December 31, 2015. The unaudited financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2014.
For the period ended March 31, 2015, the Company has no revenues and no operations. The Company has an accumulated loss of $2,211,005. In view of these matters, there is substantive doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.
Deferred Offering and Acquisition Costs
The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs will be charged against the capital raised. Should the offering be terminated, the deferred offering costs will be charged to operations during the period in which the offering is terminated. Direct acquisition costs will be expensed as incurred.
As of March 31, 2015 and 2014, the Company did not have Level 1, 2, or 3 financial assets or liabilities.
Cash and cash equivalents includes all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less.
Property and equipment consists of assets with useful lives longer than one year. Useful lives for assets have been determined to be 5 years for the Company.
The Company has yet to realize revenues from operations. Once the Company has commenced operations, it will recognize revenues when delivery of goods or completion of services has occurred provided there is persuasive evidence of an agreement, acceptance has been approved by its customers, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable.
The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has no common stock equivalents and has incurred losses for the period ended March 31, 2015, no dilutive shares are added into the loss per share calculations.
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements presentation.
Property and equipment consists of computer equipment that is stated at cost of $8,420 and $4,214 less accumulated depreciation of $1,194 and $983 at March 31, 2015 and December 31, 2014, respectively. Depreciation expense was $211 for the periods ended March 31, 2015 and March 31, 2014. Depreciation expense is computed using the straight-line method over the estimated useful life of the assets, which is five years for computer equipment.
The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets were $24,770 and $24,770 less accumulated amortization of $2,693 and $1,954 for the periods ended March 31, 2015 and December 31, 2014, respectively. For the periods ended March 31, 2015 and March 31, 2014, the amortization expense recorded was $739 and $239, respectively.
A company for which the Company’s former Secretary-Treasurer and CFO is also serving as CFO, has paid $73,610 on the Company’s behalf. The amount outstanding as of March 31, 2015 and December 31, 2014 was $43,056 and $56,155, respectively. During the periods ended March 31, 2015 and March31, 2014, the Company recorded $1,078 and $856, respectively of imputed interest on the amount owed to the related party based on an interest rate of 8%.
During 2014, the Company entered into a license agreement with a programming company in which one of our directors is Chief Marketing Officer. Through the licensing agreement, we obtained a perpetual license to use the programming code created by a video management platform as a base to develop our telemedicine video service for a license fee of $20,000. The license fee is recorded as an Intangible Asset and Accounts Payable on the Balance Sheet.
The Company rents its Culver City, CA office space from a company owned by our CEO. The imputed rent expense of $500 per month is recorded in the Consolidated Statement of Operations and Additional Paid in Capital in the Balance Sheet.
The officers of the Company incur personal expenses on behalf of the Company. The amounts outstanding as of March 31, 2015 and December 31, 2013 were $25,076 and $30,181, respectively.
At March 31, 2015 and December 31, 2014, the Company has a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.
The Company did not identify any material uncertain tax positions of the Company on returns that have been filed or that will be filed. The Company has not had operations and has deferred items consisting entirely of unused Net Operating Losses.. Since it is not thought that this Net Operating Loss will ever produce a tax benefit, even if examined by taxing authorities and disallowed entirely, there would be no effect on the financial statements.
The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the periods ended March 31 2015, and March 31, 2014 the Company did not recognize nor accrue any interest or penalties.
On December 23, 2014 the Company issued $213,337 convertible promissory notes (the “Notes”) and warrants to purchase shares of common stock to four individual investors. The overall terms of the Notes are as follows:
● Interest rate: 12% per annum. During the period ended March 31, 2015, the Company recorded $6,969 of accrued interest.
● Due date: One year after the registration statement registering the shares of common stock underlying the Notes for resale is declared effective. The Company is to pay the principal amount and all accrued and unpaid interest on or before the due date.
● Redemption right: Any time the closing price of the Company’s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the Notes, following written notice to the holders of the Notes.
● Optional Conversion: At the option of the holders, the Notes may be converted into shares of the Company’s common stock at a conversion price equal to $0.35 per share.
● Additionally, if the Company elects to exercise the redemption right, the holders have the opportunity to elect to take the cash payment or to convert all or any portion of the Notes into shares of the Company’s common stock.
● The conversion price is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.
● The Notes are senior in rank to any other debt held by our officers, directors or affiliates and may not be subordinated to any other debt issued by us without the written consent of the holder.
● Warrants: The holders of the Notes are granted the right for three years to purchase 609,534 additional shares of common stock at $.35 per share.
● During the time that any portion of these Notes are outstanding, if any Event of Default occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the “Cure Period”), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder’s election, immediately due and payable in cash. The holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company’s common stock pursuant to the Optional Conversion rights disclosed above.
● The Company’s Condensed Consolidated Balance Sheets report the following related to the convertible promissory note:
March 3l, 2015
Principal amount $ 213,337
Unamortized debt discount (26,178 )
Net carrying amount $ 187,159
The Company valued the warrants as the difference in the value of the Note at its stated interest rate of 12% and the fair value of the Note at its discounted value using an expected borrowing rate of 18%.
For the period ended March 31, 2015, none of the debt had been converted and no warrants to purchase common stock had been exercised.
Under the guidance of ASC 470-20 Debt With Conversion and Other Options, the common shares of the Company, pending being listed on the OTC, and the net settlement requirements of the warrants will be analyzed at the end of each quarter to determine if the conversion does become readily convertible to cash which would require derivative accounting calculations and recording.
Note 8. Preferred and Common Stock
The total number of shares of preferred stock which the Company shall have authority to issue is 10,000,000 shares with a par value of $0.001. There have been no preferred shares issued as of March 31, 2015.
The total number of shares of common stock which the Company shall have authority to issue is 100,000,000 shares with a par value of $0.001.
On January 24, 2015, the Company authorized the issuance of 400,000 shares for consulting services at a value of $40,000 that will be amortized over the life of the contract.
On February 23, 2015, the Company authorized the issuance of 60,000 shares for consulting services for a value of $6,000 that will be amortized over the life of the contract.
As of the period ended March 31, 2015, the Company has 16,881,000 shares of $0.001 par value common stock issued and outstanding.
The Company is currently conducting an offering of up to $1,200,000 convertible secured notes. On December 23, 2014, the Company closed the initial offering (See Footnote 7). During the period ended March 31, 2015, the Company received $146,100 in funds as part of the second part of the original offering. The receipt of these funds was recorded as a short term liability for the period ended March 31, 2015. The second part of the original offering was closed on April 9, 2015 and convertible notes and warrants were issued.
On January 24, 2015, the Company authorized the issuance of 400,000 warrants that were issued as part of a consulting agreement extension that expired on October 21, 2015. The fair value of the warrants are $32,187 and the Company recorded $7,153 as consulting expense and $25,034 as prepaid expense to be amortized over the life of the contract which expires in October, 2015.
The following is a summary of the status of all of the Company’s warrants as of March 31, 2015 and changes during the three months ended on that date:
Outstanding at January 1, 2015 - $ -
Granted 400,000 $ 0.35
Outstanding at March 31, 2015 400,000 $ 0.35
Commitments, Contingencies
Note 9. Commitments, Contingencies
Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties’ efforts to satisfy all of the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the “Share Exchange Agreement”) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (“Form 8A”) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the “Converted Offering”), to be conducted pursuant to Regulation D, as promulgated under the Securities Act.
As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419, but was unable to satisfy the SEC’s concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.
As a result of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. As a result of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation.
Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining at this time the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. In light of the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company’s Balance Sheet for the $90,000 that was subject to the Consent.
On or about June 23, 2014, we entered into a license agreement with Bistromatics Corp., to which one of our directors is Chief Marketing Officer, pursuant to which we obtained a perpetual license to use the programming code created by a video management platform as a base to develop our telemedicine video service for a license fee of $20,000 due by September 31, 2014. The parties entered into an addendum extending the due date of the license fee to December 31, 2014. Intellectual property developed as a result of this license, will be our property; but Bistromatics will retain the intellectual property for the original code base. We may resell or license the resulting telemedicine platform for an extended license fee of $10,000 for each additional instance the code base will be used. Through this agreement, Bistromatics Corp. built our PHZIO.com platform; our director purchased the domain name on behalf of the Company and retains no rights to same. On March 16, 2015, the Company extended the licensing fee payment agreement until July 1, 2015. The Company made an initial payment of $5,000 with the remaining fees to be to be paid on or before July 1, 2015.
The Company rents its Culver City, CA office space from a company owned by our CEO. The rental agreement provides for the value of the rent of $500 per month be recorded as contributed towards the founding eWellness and its operations. During the period ended March31, 2015, we have recorded this rent payment in the Consolidated Statements of Operations and Additional Paid in Capital on the Balance Sheet.
In May 2014, the Company signed an Office Service Agreement for office space in New York, New York. A deposit of $17,874 was paid and recorded in prepaid expense. The utilization of the office space began on August 1, 2014 and terminated at December 31, 2014. The Company negotiated a settlement of $5,500 in April, 2015 for the cancellation of the agreement. The settlement resulted in a gain on extinguishment of debt of $11,323.
On January 24, 2015, the Company received $20,000 in exchange for a 90-day Promissory Note at an interest rate of 12% per annum. For the period ended March 31, 2015, the Company recorded $447 of accrued interest for this note.
On January 24, 2015 the Company extended a previous consulting and service agreement with a consultant from April 21, 2015 to October 20, 2015 in exchange for 400,000 shares of restricted common stock and 400,000 callable common stock purchase warrants at a strike price of $0.35 per share. The fair value of the common stock issued for the services is $40,000 and the Company recorded $8,889 as consulting expense and $31,111 as prepaid expense to be amortized over the life of the contract. The fair value of the warrants issued for services is $32,187 and the Company recorded $7,153 as consulting expense and $25,034 as prepaid expense to be amortized over the life of the contract. With this extension agreement, the Company is to pay $10,000 per month consulting fee beginning with February 1, 2015 through the end of the agreement. For the period ended March 31, 2015, the Company accrued $20,000 for these consulting fees.
On February 14, 2015, the Company entered into a one-year agreement with BMT, Inc. as a consultant and advisor in connection with certain business development advisory. This agreement is on an at-will basis as determined by the company in exchange for cash compensation to be invoiced monthly. The total compensation paid to date on this agreement is $11,950.
On February 23, 2015, the Company entered into a one-year agreement with a consultant in connection with certain corporate finance, investor relations and related business matters in exchange for 60,000 shares of restricted common stock. The fair value of the services is $6,000 and the Company recorded $500 as consulting expense and $5,500 as prepaid expense to be amortized over the life of the contract that expires in February, 2016.
From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, management believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.
The Company has one operating segment, which was identified based upon the availability of discrete financial information and the chief operating decision makers’ regular review of financial information.
On April 1, 2015, the Company entered into an Operating Agreement with Evolution Physical Therapy (“EPT”), a company owned by one of the Company’s officers, wherein it is agreed that EPT would be able to operate the Company’s telemedicine platform www.phzio.com and offer it to selected physical therapy patients of EPT. The Company is to receive 75% of the net insurance reimbursements from the patient for use of the platform. The Company will advance capital requested by EPT for costs specifically associated with operating the www.phzio,com platform and associated physical therapy treatments – computer equipment, office or facilities rental payments, physical therapist or physical therapy assistant, administrative staff, patient induction equipment, office supplies, utilities and other associated operating costs. It is anticipated that the operation of the platform by EPT will generate positive cash flow within 90 days from the start of patient induction.
On April 9, 2015, the Company closed a second round of its private placement offering with eight accredited investors in which it raised gross proceeds of $270,080 (including an aggregate of $123,980 that was converted from certain other outstanding notes, including accrued interest, and future contractual cash consulting fees) and sold that same amount of Series A Senior Convertible Redeemable Notes convertible into shares of the Company’s common stock, par value $0.001 per share at $0.35 per share and Series A Warrants, all pursuant to separate Securities Purchase Agreements entered into with each investor. The Warrants are exercisable to purchase up to 834,857 shares of Common Stock. The sale was part of a private placement offering in which the Company offered for sale a maximum of $1,200,000 principal amount of convertible notes.
On April 17, 2015, the Company entered into an agreement with Akash Bajaj, M.D., M.P.H. The agreement is for Dr. Bajaj to serve as a consultant and as the Chairman of the Company’s Clinical Advisory Board. The term of the agreement is for one year with annual renewal as desired. The agreement further sets the hourly rate to be paid at $225 per hour with payment to be at the end of each month. Further, the Company granted Dr. Bajaj a five-year non-statutory option to purchase 100,000 shares of common stock at a price of $.35 per share. The options will vest over a 12 month period at 8,333 per month. As the Company’s stock is not yet publicly traded, the value of the options are deemed to be zero.
On May 7, 2015, Evolution Physical Therapy inducted the first patient using the Company’s telemedicine platform www.phzio.com.
Name: DGT_GoingConcernPolicyTextBlock
Name: us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy
Schedule of Convertible Promissory Note
Preferred and Common Stock (Tables)
The Company (Details Narrative)
The Company (Details Narrative) (USD $)
Share Exchange Agreement [Member]
Unregistered common stock issued 9,200,000
Number of common stock returned to company by the officer 5,000,000
Number of shares assigned to shareholders from the holdings of officer 2,500,000
Number of shares owned by the shareholders, total 11,700,000
Additional number of common shares assigned to other parties 2,100,000
Percentage of issued and outstanding common stock own by shareholders of subsidiary 76.97%
Number of shares of common stock outstanding 15,200,000
Additional number of common shares assigned to other parties.
Name: DGT_AdditionalNumberOfCommonSharesAssignedToOtherParties
Number of shares assigned to shareholders form the holdings of officer.
Name: DGT_NumberOfSharesAssignedToShareholdersFormHoldingsOfOfficer
Number of shares owned by the shareholders, total.
Name: DGT_NumberOfSharesOwnedByShareholders
Percentage of issued and outstanding common stock own by shareholders of subsidiary.
Name: DGT_PercentageOfIssuedAndOutstandingCommonStockOwnByShareholdersOfSubsidiary
Unregistered common stock issued during the period, shares.
Name: DGT_StockIssuedDuringPeriodSharesIssuanceOfUnregisteredStock
Accumulated loss $ 2,218,158 $ 1,901,279
Property and equipment $ 7,226 $ 3,231
Depreciation expense 211 211
Property and equipment useful life 5 years
Property and equipment 8,420 4,214
Accumulated depreciation $ 1,194 $ 983
Intangible Assets (Details Narrative) (USD $)
Intangible assets $ 22,077 $ 22,816
SoftwareLlicenseMember
Intangible assets 24,770 24,770
Accumulated amortization 2,693 1,954
Amortization expense $ 739 $ 239
Chief Marketing Officer [Member]
Amount paid by related parties $ 73,610
Accounts Payable-Related Party 43,056 56,155
Percentage of interest rate of related party 8.00% 12.00%
License fee 10,000 20,000
Rent expense 500
Accrued expenses - related party $ 25,076 $ 30,181 $ 25,076 $ 30,181
Name: us-gaap_AccountsPayableRelatedPartiesNoncurrent
Name: us-gaap_PaymentsForRent
Issuance of convertible promissory notes $ 213,337 $ 213,337
Interest rate 12.00% 8.00%
Principal amount due date Dec. 31, 2015
Accrued interest 6,969 447
Redemption right: Any time the closing price of the Company’s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the Notes, following written notice to the holders of the Notes.
Common stock conversion price per share $ 0.35
Purchase of additional shares of common stock 609,534
Purchase of common stock purchase price per share $ 0.35
Debt instrument accrued interest rate 150.00% 12.00% 12.00%
Percentage of expected borrowing rate 18.00%
Purchase of warrants exercised
Percentage Of Expected Borrowing Rate.
Name: DGT_PercentageOfExpectedBorrowingRate
Purchase of additional shares of common stock.
Name: DGT_PurchaseOfAdditionalSharesOfCommonStock
Purchase of warrants exercised.
Name: DGT_PurchaseOfWarrantsExercised
Convertible Notes Payable - Schedule of Convertible Promissory Note (Details)
Convertible Notes Payable - Schedule of Convertible Promissory Note (Details) (USD $)
Principal amount $ 213,337 $ 213,337
Unamortized debt discount (26,178)
Net carrying amount $ 187,159 $ 178,433
Preferred and Common Stock (Details Narrative)
Preferred and Common Stock (Details Narrative) (USD $)
Shares issued during period for consulting services $ 6,000 $ 40,000 $ 9,389
Shares issued during period for consulting services, shares 60,000 400,000
Convertible secured notes 1,200,000
Second part of the original offering 146,100
Prepaid expense 17,874
Authorized issuance warrants were issued 400,000
Fair value of warrants 32,187
Consulting expense 7,153
Prepaid expense $ 25,034
Authorized issuance warrants were issued.
Name: DGT_AuthorizedIssuanceWarrantsWereIssued
Consulting expense.
Name: DGT_ConsultingExpenses
Fair value of warrants.
Name: DGT_FairValueOfWarrants
Second part of the original offering.
Name: DGT_SecondPartOfOriginalOffering
Name: us-gaap_SecuredDemandNotes
Preferred and Common Stock - Summary of Warrant Activity (Details)
Preferred and Common Stock - Summary of Warrant Activity (Details) (Warrant [Member], USD $)
Number of Warrants Outstanding, Beginning Balance
Number of Warrants Granted 400,000
Number of Warrants Cancelled
Number of Warrants outstanding, Ending Balance 400,000
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance
Weighted Average Exercise Price, Warrants Granted $ 0.35
Weighted Average Exercise Price, Warrants Exercised
Weighted Average Exercise Price, Warrants Cancelled
Weighted Average Exercise Price, Warrants outstanding, Ending Balance $ 0.35
Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price.
Name: DGT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price.
Name: DGT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
Share Based Compensation Arrangement By Share Based Payment Award Non Option Grand In Period Weighted Average Exercise Price.
Name: DGT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share.
Name: DGT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare
Commitments, Contingencies (Details Narrative)
Commitments, Contingencies (Details Narrative) (USD $)
Consulting Services Agreement [Member]
April 20, 2015 To October 20, 2015 [Member]
Escrow Trust [Member]
MHI Patients [Member]
Bistromatics Corp., [Member]
BMT Inc., [Member]
Percentage of subscription proceeds 10.00%
Trust account balance $ 90,000
Percentage of returned funds 90.00%
Percentage of funds proceed 10.00%
Percentage of required funds 90.00%
Escrowed funds 100,000
Proceeds from escrowed funds 10,000
Return of escrowed funds 90,000
Percentage of billing fee 20.00%
Extended license fee 10,000
Balance due 5,000
Due date Dec. 31, 2015 Aug. 01, 2014 Sep. 15, 2014
Prepaid expense 17,874 25,034 5,500 31,111 25,034
Negotiated a settlement for cancellation agreement 5,500
Received promissory notes 20,000
Interest rate 12.00% 150.00% 12.00%
Accured interest 6,969 447
Restricted common stock shares 60,000 400,000
Common stock purchase of warrants 400,000
Warrant price per share $ 0.35 $ 0.35
Consulting fee 20,000 500 8,889 7,153 10,000
Shares issued for services 6,000 40,000 9,389 6,000 40,000 32,187
Shares have not issued 60,000 400,000
Compensation paid $ 11,950
Balance Due Of Related Parties.
Name: DGT_BalanceDueOfRelatedParties
Name: DGT_ConsultingFees
Extended license fee.
Name: DGT_ExtendedLicenseFee
Negotiated a settlement for cancellation agreement.
Name: DGT_NegotiatedSettlementForCancellationAgreement
Percentage Of Billing Fee.
Name: DGT_PercentageOfBillingFee
Percentage of funds proceed.
Name: DGT_PercentageOfFundsProceed
Percentage of required funds.
Name: DGT_PercentageOfRequiredFunds
Percentage of returned funds.
Name: DGT_PercentageOfReturnedFunds
Percentage of subscription proceeds.
Name: DGT_PercentageOfSubscriptionProceeds
Proceeds from escrowed funds.
Name: DGT_ProceedsFromEscrowedFunds
Return of escrowed funds.
Name: DGT_ReturnOfEscrowedFunds
Stock Issued During Period Shares Purchase Of Warrants.
Name: DGT_StockIssuedDuringPeriodSharesPurchaseOfWarrants
Name: us-gaap_DeferredCompensationArrangementWithIndividualDistributionsPaid
Subsequent Events (Details Narrative) (USD $)
Akash Bajaj [Member]
12 Month [Member]
Percentage of receive insurance reimbursements from patient 75.00%
Proceeds from accredited investors $ 270,080
Aggregate value of convertible other outstanding notes, accrued interest, future cash consulting fees 123,980
Price per share $ 0.35
Warrants issued for exercisable to purchase common stock 834,857
Convertible notes 1,200,000
Payment to be paid per hour end of each month $ 225
Term of non-statutory option to purchase 5 years
Option to purchase common shares 100,000
Share price $ 0.35
Stock option vest per month 8,333
Aggregate value of convertible other outstanding notes.
Name: DGT_AggregateValueOfConvertibleOtherOutstandingNotes
Option to purchase common shares.
Name: DGT_OptionToPurchaseCommonShares
Payment to be paid per hour end of each month.
Name: DGT_PaymentToBePaidPerHourEndOfEachMonth
Percentage of receive insurance reimbursements from patient.
Name: DGT_PercentageOfReceiveInsuranceReimbursementsFromPatient
Proceeds from accredited investors.
Name: DGT_ProceedsFromAccreditedInvestors
Term of non-statutory option to purchase.
Name: DGT_TermOfNonstatutoryOptionToPurchase
Warrants issued for exercisable to purchase common stock.
Name: DGT_WarrantsIssuedForExercisableToPurchaseCommonStock